Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide versus fexofenadine for seasonal allergic rhinitis
ACTRN12626000162314Phase 4Completed
- Sponsor
- Damascus University
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of budesonide and fexofenadine in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Damascus University. Primary endpoint: Symptom severity. Started Jul 2021; status: completed.
02
Drugs
budesonidefexofenadine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on ACTRN12626000162314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000162314.